26 completed. 26 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 26 |
| Phase 2 | 13 | Completed 13 |
Follow Liver Failure: new trials by email Literature Review of Liver Failure trials Research Report on Liver Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers Single Dose G1090N, Multiple dosing of G1090N - Acute-on-Chronic Liver Failure | Phase 1 | Completed | Genfit | 52 | 2025-08-26 | 2026-01-16 |
| miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial miroliverELAP treatment - Acute Liver Failure, Acute Liver Injury, Drug Induced | Phase 1 | Completed | Miromatrix Medical Inc. | 10 | 2024-10-05 | 2026-03-06 |
| Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients Bone marrow mesenchymal stem cells (low dose), Solvent of CG-BM1, Bone marrow mesenchymal stem cells (medium dose) - Acute-On-Chronic Liver Failure | Phase 1 / Phase 2 | Completed | GuangZhou Cellgenes Biotechnology Co., Ltd. | 100 | 2023-03-01 | 2026-10-21 |
| Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF) Branch Chain Amino Acid, Lactulose - Hepatic Encephalopathy, Acute-On-Chronic Liver Failure | Phase 1 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 114 | 2023-01-17 | 2025-06-08 |
| Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy PPI deprescribing - Hepatic Encephalopathy | Phase 1 / Phase 2 | Completed | Duke University | 33 | 2022-01-03 | 2026-09-10 |
| Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment Fecal microbiota transplantation delivery through colonoscopy, Fecal microbiota transplantation delivery through oral capsules - Hepatic Encephalopathy, Dysbiosis | Phase 1 | Completed | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 33 | 2021-04-07 | 2026-09-18 |
| Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment Icenticaftor - Hepatic Failure | Phase 1 | Completed | Novartis Pharmaceuticals | 40 | 2020-10-30 | 2024-06-20 |
| Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF Branched chain amino acid, Lactulose - Hepatic Encephalopathy, Acute-On-Chronic Liver Failure | Phase 1 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 70 | 2019-11-01 | 2022-08-16 |
| FMT in Cirrhosis and Hepatic Encephalopathy Fecal Microbial transplant Capsules, Fecal Microbial Transplant Enema, Placebo - Cirrhosis, Hepatic Encephalopathy | Phase 1 / Phase 2 | Completed | VA Office of Research and Development | 60 | 2019-07-29 | 2025-05-25 |
| An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function BMS-986231 - Liver Dysfunction, Liver Insufficiency | Phase 1 | Completed | Bristol-Myers Squibb | 76 | 2018-05-25 | 2020-08-27 |
| Oral Fecal Transplant in Cirrhosis FMT, Placebo - Hepatic Encephalopathy, Cirrhosis, Liver | Phase 1 | Completed | Virginia Commonwealth University | 20 | 2017-06-12 | 2021-05-19 |
| Normothermic Liver Preservation Trial OrganOx metra - End Stage Liver Disease, Liver Diseases | Phase 1 / Phase 2 | Completed | University of Alberta | 106 | 2017-02-24 | 2024-07-25 |
| Fecal Transplant for Hepatic Encephalopathy FMT - Hepatic Encephalopathy | Phase 1 / Phase 2 | Completed | University of Alberta | 3 | 2016-04-12 | 2022-06-10 |
| Fecal Transplant in Recurrent Hepatic Encephalopathy Fecal transplant - Hepatic Encephalopathy, Cirrhosis | Phase 1 | Completed | Jasmohan Bajaj | 20 | 2015-10-01 | 2022-07-05 |
| Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study Fecal Microbiota Transplant - Hepatic Encephalopathy | Phase 1 / Phase 2 | Completed | University of Alberta | 4 | 2014-07-23 | 2021-10-04 |
| Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients Autologous regulatory T cell product - End-stage Liver Disease | Phase 1 / Phase 2 | Completed | Guy's and St Thomas' NHS Foundation Trust | 9 | 2014-06-01 | 2019-01-10 |
| Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects Lofexidine Hydrochloride (HCl) tablets - Liver Failure | Phase 1 | Completed | USWM, LLC (dba US WorldMeds) | 24 | 2014-06-01 | 2018-02-23 |
| Mesenchymal Stem Cells After Renal or Liver Transplantation Mesenchymal Stem Cells - Liver Failure, Kidney Failure | Phase 1 / Phase 2 | Completed | University of Liege | 40 | 2012-02-01 | 2022-06-14 |
| Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients Raltegravir potassium - HIV Infection, Liver Failure | Phase 1 / Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 14 | 2010-05-01 | 2026-04-06 |
| The Effect of Probiotics (VSL) on Portal Hypertension Probiotic - Portal Hypertension | Phase 1 / Phase 2 | Completed | University of Alberta | 18 | 2009-12-01 | 2012-01-20 |
Showing 20 of 26. Sign in to see all of them.
Hepatic Encephalopathy (11) · Fibrosis (8) · Acute-On-Chronic Liver Failure (6) · End Stage Liver Disease (5) · Liver Diseases (3) · Hepatic Insufficiency (2) · Liver Failure, Acute (2) · Brain Diseases (1) · Brain Edema (1) · Carcinoma, Hepatocellular (1) · Chemical and Drug Induced Liver Injury (1) · Dysbiosis (1) · HIV Infections (1) · Heart Failure (1)
Digestive System Diseases (26) · Hepatic Insufficiency (24) · Liver Diseases (23) · Central Nervous System Diseases (12) · Nervous System Diseases (12) · Brain Diseases (11) · Brain Diseases, Metabolic (11) · Metabolic Diseases (11) · Nutritional and Metabolic Diseases (11) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Liver Failure, Acute (5) · Urogenital Diseases (4) · Female Urogenital Diseases (3)
Fecal Microbiota Transplantation (2) · Lactulose (2) · Amino Acids (1) · Amino Acids, Branched-Chain (1) · Probiotics (1) · Raltegravir Potassium (1) · Tablets (1) · glycerol phenylbutyrate (1) · icenticaftor (1) · latrepirdine (1) · lofexidine (1)
University of Alberta (4) · Post Graduate Institute of Medical Education and Research, Chandigarh (2) · Virginia Commonwealth University (2) · ANRS, Emerging Infectious Diseases (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · Duke University (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Genfit (1) · GuangZhou Cellgenes Biotechnology Co., Ltd. (1) · Guy's and St Thomas' NHS Foundation Trust (1) · Jasmohan Bajaj (1) · Miromatrix Medical Inc. (1) · Novartis Pharmaceuticals (1)
United States (11) · Canada (4) · France (2) · India (2) · Belgium (1) · China (1) · Hungary (1) · Iran (1) · Italy (1) · Poland (1) · Ukraine (1) · United Kingdom (1)
Charles Gorodetzky, MD, PhD (1) · Deborah Haller (1) · Dina Kao, MD (1) · Giovanna Lombardi, PhD (1) · Jack Lake, MD (1) · James Longstreth, PhD (1) · James Ronald, MD PhD (1) · James Shapiro, MD, PhD (1) · Jasmohan Bajaj, MD (1) · Jasmohan S Bajaj, MD, MSc (1) · Jasmohan S. Bajaj, MD MS (1)
PMID 20512995, PMID 25715177, PMID 28284916, PMID 30568347, PMID 31038755, PMID 31751317, PMID 37975059, PMID 38109364, PMID 38153225, PMID 41503571, PMID 6749458, PMID 818729
2009 (1), 2017 (1), R21TR002024 (1), U01AT004428 (1)